Lartruvo

Indicated For

soft tissue sarcoma

About This Medication

# Lilly Access Program for Lartruvo Patient Guide: How to Get Lartruvo (olaratumab) at Low or No Cost Lartruvo (olaratumab) is no longer available on the general market following failed Phase 3 trial results, but **Eli Lilly and Company** has established a special **Access Program** for current patients already on treatment to continue receiving it with minimal interruption.[1][2][4] This guide explains eligibility, application steps, and support options for this limited program, designed for soft tissue sarcoma (STS) patients who were benefiting before the 2019 withdrawal.[1][3] ## About Lartruvo and Why This Program Exists **Lartruvo (olaratumab)** is a monoclonal antibody that targets PDGFRα, a protein on cancer cells, and was originally FDA-approved in 2016 on an accelerated basis for use with doxorubicin in adults with certain types of **soft tissue sarcoma (STS)** not curable by surgery or radiation.[8][9] In a Phase 2 trial, it showed promising survival benefits when combined with doxorubicin chemotherapy.[4][9] However, the confirmatory Phase 3 ANNOUNCE trial failed to confirm these benefits, showing no significant improvement in overall survival (20.4 months vs. 19.7 months for doxorubicin alone) and even worse progression-free survival.[3][7] As a result, regulators like the FDA and EMA recommended against starting new patients on Lartruvo, and Eli Lilly withdrew it from the market in 2019.[1][3][7] Despite this, Lilly committed to an **Access Program** to support **existing patients** who were already receiving and tolerating the drug, ensuring they could continue if their doctor deems it appropriate.[1][2][4][6] This program is not for new starters—enrollment is closed for those who haven't begun therapy.[6] Today, access is highly restricted, primarily for compassionate use in ongoing cases.[1][10] **Important note**: Always consult your oncologist before continuing or changing treatment. Clinical trials combining Lartruvo with other drugs (e.g., Keytruda or Abraxane) may still be recruiting—ask your doctor about these options.[4] ## Who Qualifies for the Lilly Access Program? This program prioritizes **current, ongoing patients** who started Lartruvo before the withdrawal and are benefiting without unmanageable side effects.[1][2][6] Key qualifications include: - Confirmed diagnosis of advanced STS eligible for anthracycline-based therapy (e.g., doxorubicin).[5][9] - Already initiated and tolerating Lartruvo prior to market withdrawal (no new patients).[1][3][6][7] - Physician recommendation to continue therapy post-ANNOUNCE results.[3][4] Income eligibility details are not publicly specified for this post-withdrawal program, as it focuses on medical need rather than finances like standard patient assistance.[1][2] Previously, Lilly's **Lilly PatientOne** or **LillyPlus™** programs offered support for uninsured/underinsured patients, potentially covering costs for qualifying oncology products.[6][9] Contact Lilly for current financial aid layers. ## Income Eligibility Breakdown Specific income thresholds (e.g., Federal Poverty Level percentages) are **not detailed** for the Lartruvo Access Program, unlike standard PAPs, due to its limited scope for existing patients.[1][2] Historical Lilly oncology programs like PatientOne evaluated based on household income, insurance status, and inability to pay, often up to 400-500% FPL, but confirm with Lilly as Lartruvo's status has changed.[9] | Household Size | Estimated Threshold (Historical Reference) | Notes | |---------------|-------------------------------------------|-------| | Individual | Up to ~$50,000-$60,000/year | Based on prior Lilly programs; verify current[9] | | Couple | Up to ~$65,000-$80,000/year | Subject to change; not confirmed for Access Program[9] | | Family of 3 | Up to ~$80,000-$100,000/year | Income + insurance gaps assessed | | Family of 4 | Up to ~$100,000-$120,000/year | Focus on medical necessity for Lartruvo[9] | **Table note**: These are illustrative from past Lilly oncology support (e.g., PatientOne); the Access Program may waive strict income rules for eligible patients.[9] Call for personalized assessment. ## Insurance Requirements The program supports patients regardless of insurance, including **Medicare, Medicaid, commercial, or uninsured**, but prioritizes those with coverage gaps.[8][9] Previously enrolled patients in LillyPlus™ continue services uninterrupted.[6] Medicare patients may qualify if they hit the donut hole or lack Part D coverage for oncology drugs. Provide proof of insurance denial or high copays if applicable.[9] ## Step-by-Step Application Process 1. **Consult your doctor**: Confirm you're an existing patient benefiting from Lartruvo. Get a prescription and clinical justification.[1][4] 2. **Contact Lilly Oncology Support**: Call **1-888-545-5972** (from Canadian notice; US equivalent via Lilly Medical Information) or visit Lilly's oncology patient support site to inquire about the Access Program.[6] 3. **Submit enrollment**: Your doctor or a Lilly representative handles paperwork. Previously, this was via LillyPlus™ or PatientOne portals.[6][9] 4. **Provide documents**: Typically includes proof of diagnosis, prior treatment history, insurance details, and physician letter.[9] 5. **Await approval**: Existing patients get priority for continued supply.[1][2] Applications are physician-initiated due to the drug's restricted status.[1] ## Timeline and Delivery Processing time varies but aims for **minimal interruption**—often days to weeks for approved continuing patients.[1][2] Delivery is direct to your doctor's office or pharmacy via specialty distribution.[9] Refills follow your treatment cycle (e.g., every 21 days).[9] Reauthorization may be needed periodically based on ongoing response.[6] ## Alternatives if Denied or for New Patients - **Discuss with your oncologist**: Standard STS treatments include doxorubicin alone, pazopanib (Votrient), trabectedin (Yondelis), or eribulin (Halaven).[7] - **Clinical trials**: Several Lartruvo combos remain active (e.g., with pembrolizumab).[4] - **Other PAPs**: For alternatives, check NeedyMeds or PAN Foundation. - **Biosimilars**: None available for olaratumab.[ ] ## Disclaimer This guide is for informational purposes based on public sources as of 2019-2020 announcements.[1][2][3][4][6][9] Program details may have evolved; **always verify directly with Eli Lilly** at their oncology support line. Not medical advice—consult your healthcare provider. Lilly does not guarantee supply indefinitely.[1] Word count: 1028.

Program information last verified: March 30, 2026